Pacritinib Citrate
Brand name: Vonjo
Rank #496 of 500 drugs by total cost
$13.9M
Total Cost
626
Total Claims
$13.9M
Total Cost
37
Prescribers
$22K
Cost per Claim
0
Beneficiaries
627
30-Day Fills
$376K
Avg Cost/Provider
17
Avg Claims/Provider
About Pacritinib Citrate
Pacritinib Citrate (sold as Vonjo) was prescribed 626 times by 37 Medicare Part D providers in 2023, costing the program $13.9M. At $22K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 493 | Omadacycline Tosylate (Nuzyra) | $14.1M | 1,395 |
| 494 | Binimetinib (Mektovi) | $14.1M | 1,094 |
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
| 497 | Olmesartan/Hydrochlorothiazide (Olmesartan-Hydrochlorothiazide) | $13.9M | 246,637 |
| 498 | C1 Esterase Inhibitor, Recomb (Ruconest) | $13.8M | 155 |
| 499 | Sildenafil Citrate (Sildenafil Citrate) | $13.8M | 248,961 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology